Haemonetics Corporation
Detection of Reversal of an Anticoagulant Using a Clotting Assay

Abstract:

In some embodiments, the invention provides methods for detecting the reversal an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of an ecarin reagent to obtain a control ecarin clotting measurement; subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control Factor Xa clotting measurement; subjecting a sample of a blood component from a patient suspected to contain a reversal agent to a clotting assay in the presence of the ecarin reagent to obtain a patient ecarin clotting measurement; subjecting a sample of a blood component from the patient suspected to contain the reversal agent to a clotting assay in the presence of the Factor Xa reagent to obtain a patient Factor Xa clotting measurement; and comparing the control ecarin clotting measurement to the patient ecarin clotting measurement and comparing the control Factor Xa clotting measurement to the patient Factor Xa measurement.